Prospective strategies for targeting HIV-1 integrase function

被引:2
作者
Luo, Yang [1 ]
Muesing, Mark A. [1 ]
机构
[1] Aaron Diamond AIDS Res Ctr, New York, NY 10016 USA
关键词
HUMAN-IMMUNODEFICIENCY-VIRUS; SMALL-MOLECULE INHIBITORS; TYPE-1; INTEGRASE; STRAND TRANSFER; NUCLEAR IMPORT; IN-VITRO; STYRYLQUINOLINE DERIVATIVES; CONCERTED INTEGRATION; EXPERIENCED PATIENTS; COFACTOR LEDGF/P75;
D O I
10.4155/FMC.10.205
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Integration is a key step in the HIV-I life cycle in which the ends of linear viral DNA are covalently joined with host chromosomal DNA. Integrase is the highly conserved and essential viral protein that performs two catalytically related reactions that ultimately lead to the insertion of the viral genome into that of the host cell. The only chemotherapeutic agents against integrase currently available for HIV-I infected individuals are those that interrupt strand transfer, the second step of catalysis. Accordingly, this article outlines possible future strategies targeting the first catalytic step, 3' processing, as well as other nonenzymatic, yet indispensible, functions thought to be coordinated by integrase. Importantly, the interruption of irremediable recombination between viral and host DNAs represents the last step after viral entry at which an otherwise irreversible infection can be prevented.
引用
收藏
页码:1055 / 1060
页数:6
相关论文
共 71 条
[1]   Interaction of human immunodeficiency virus type 1 integrase with cellular nuclear import receptor importin 7 and its impact on viral replication [J].
Ao, Zhujun ;
Huang, Guanyou ;
Yao, Han ;
Xu, Zaikun ;
Labine, Meaghan ;
Cochrane, Alan W. ;
Yao, Xiaojian .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2007, 282 (18) :13456-13467
[2]   Styrylquinolines, integrase inhibitors acting prior to integration:: a new mechanism of action for anti-integrase agents [J].
Bonnenfant, S ;
Thomas, CM ;
Vita, C ;
Subra, F ;
Deprez, E ;
Zouhiri, F ;
Desmaële, D ;
d'Angelo, J ;
Mouscadet, JF ;
Leh, H .
JOURNAL OF VIROLOGY, 2004, 78 (11) :5728-5736
[3]   Acetylation of HIV-1 integrase by p300 regulates viral integration [J].
Cereseto, A ;
Manganaro, L ;
Gutierrez, MI ;
Terreni, M ;
Fittipaldi, A ;
Lusic, M ;
Marcello, A ;
Giacca, M .
EMBO JOURNAL, 2005, 24 (17) :3070-3081
[4]   High frequency of integrase Q148R minority variants in HIV-infected patients naive of integrase inhibitors [J].
Charpentier, Charlotte ;
Laureillard, Didier ;
Piketty, Christophe ;
Tisserand, Pascaline ;
Batisse, Dominique ;
Karmochkine, Marina ;
Si-Mohamed, Ali ;
Weiss, Laurence .
AIDS, 2010, 24 (06) :867-873
[5]   Structural basis for the recognition between HIV-1 integrase and transcriptional coactivator p75 [J].
Cherepanov, P ;
Ambrosio, ALB ;
Rahman, S ;
Ellenberger, T ;
Engelman, A .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (48) :17308-17313
[6]   Identification of an evolutionarily conserved domain in human lens epithelium-derived growth factor/transcriptional co-activator p75 (LEDGF/p75) that binds HIV-1 integrase [J].
Cherepanov, P ;
Devroe, E ;
Silver, PA ;
Engelman, A .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (47) :48883-48892
[7]   HIV-1 integrase forms stable tetramers and associates with LEDGF/p75 protein in human cells [J].
Cherepanov, P ;
Maertens, G ;
Proost, P ;
Devreese, B ;
Van Beeumen, J ;
Engelborghs, Y ;
De Clercq, E ;
Debyser, Z .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (01) :372-381
[8]   Integrase illuminated [J].
Cherepanov, Peter .
EMBO REPORTS, 2010, 11 (05) :328-328
[9]   USE OF EVOLUTIONARY LIMITATIONS OF HIV-1 MULTIDRUG RESISTANCE TO OPTIMIZE THERAPY [J].
CHOW, YK ;
HIRSCH, MS ;
MERRILL, DP ;
BECHTEL, LJ ;
ERON, JJ ;
KAPLAN, JC ;
DAQUILA, RT .
NATURE, 1993, 361 (6413) :650-654
[10]  
CHRIST F, 2010, 17 C RETR OPP INF SA